dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Syk family (type: enzyme)
Target: spleen associated tyrosine kinase

Ligand: apitolisib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.869999885559082 pIC50
Reference (Journal): Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Published in: J Med Chem

Ligand: BAY 61-3606 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner.
Published in: PLoS ONE

Ligand: cerdulatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.489999771118164 pIC50
Reference (Journal): The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Published in: J Pharmacol Exp Ther

Ligand: compound 23 [PMID: 17600705] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
Published in: Bioorg Med Chem Lett

Ligand: compound 7 [PMID: 22464456] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.449999809265137 pIC50
Reference (Journal): X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
Published in: Bioorg Med Chem Lett

Ligand: entospletinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.109999656677246 pIC50
Reference (Journal): Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
Published in: J Med Chem

Ligand: ER-27319 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5 pIC50
Reference (Journal): Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Published in: J Med Chem

Ligand: GSK143 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.119999885559082 pIC50
Reference (Journal): Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Published in: Bioorg Med Chem Lett

Ligand: GSK2646264 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Published in: Bioorg Med Chem Lett
Target family: Synuclein proteins (type: other_protein)
Target: synuclein alpha

Ligand: prasinezumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pKd
Reference (Journal): Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-&#x3b1;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Published in: JAMA Neurol

Ligand: cinpanemab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7 pKd
Reference (Journal): Development of an aggregate-selective, human-derived &#x3b1;-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
Published in: Neurobiol Dis

Ligand: prasinezumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 10.319999694824219 pKd
Reference (Journal): Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-&#x3b1;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Published in: JAMA Neurol
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 1

Ligand: [3H]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 4

Ligand: [14C]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 2

Ligand: [3H]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 1

Ligand: [14C]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 2

Ligand: [14C]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System A-like transporters (type: transporter)
Target: sodium-coupled neutral amino acid transporter 4

Ligand: [3H]glycine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [3H]alanine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [14C]glycine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System N-like transporters (type: transporter)
Target: Sodium-coupled neutral amino acid transporter 5

Ligand: [3H]histidine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [14C]histidine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: System N-like transporters (type: transporter)
Target: Sodium-coupled neutral amino acid transporter 3

Ligand: [3H]glutamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [14C]glutamine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Target family: T1: Proteasome (type: enzyme)
Target: proteasome 20S subunit beta 2

Ligand: MG-132 (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pKi
Reference (Journal): Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Published in: J Med Chem
Target family: T1: Proteasome (type: enzyme)
Target: proteasome 20S subunit beta 1

Ligand: compound 3b [PMID: 24946214] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.619999885559082 pKi
Reference (Journal): Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Published in: Eur J Med Chem
Target family: T1: Proteasome (type: enzyme)
Target: proteasome 20S subunit beta 9

Ligand: zetomipzomib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.880000114440918 pIC50
Reference (Journal): Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Published in: J Med Chem

Ligand: zetomipzomib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.75 pIC50
Reference (Journal): Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Published in: J Med Chem
Target family: T1: Proteasome (type: enzyme)
Target: proteasome 20S subunit beta 8

Ligand: zetomipzomib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Published in: J Med Chem

Ligand: zetomipzomib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.409999847412109 pIC50
Reference (Journal): Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Published in: J Med Chem

Ligand: ONX-0914 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7 pIC50
Reference (Journal): A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.
Published in: Nat Med

Ligand: HT1042 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.380000114440918 pKi
Reference (Journal): Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.
Published in: ACS Med Chem Lett
Target family: T1: Proteasome (type: enzyme)
Target: proteasome 20S subunit beta 2

Ligand: zetomipzomib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.21999979019165 pIC50
Reference (Journal): Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Published in: J Med Chem
Target family: T2: Glycosylasparaginase precursor (type: enzyme)
Target: taspase 1

Ligand: yzm18 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.53000020980835 pIC50
Reference (Journal): Design, syntheses, and evaluation of Taspase1 inhibitors.
Published in: Bioorg Med Chem Lett
Target family: TAF1 family (type: enzyme)
Target: TATA-box binding protein associated factor 1

Ligand: BAY-299 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pIC50
Reference (Webpage): BAY-299 A probe for BRD1 and TAF1
Target family: TAIRE subfamily (type: enzyme)
Target: cyclin dependent kinase 18

Ligand: compound 77 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem
Target family: TAO subfamily (type: enzyme)
Target: TAO kinase 1

Ligand: AMG28 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of &#x3b2;-Coronaviruses.
Published in: J Med Chem
Target family: TAO subfamily (type: enzyme)
Target: TAO kinase 2

Ligand: AMG28 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.039999961853027 pIC50
Reference (Journal): Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of &#x3b2;-Coronaviruses.
Published in: J Med Chem
Target family: TAO subfamily (type: enzyme)
Target: TAO kinase 1

Ligand: compound 18 [PMID: 20873740] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.380000114440918 pIC50
Reference (Journal): Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Published in: J Med Chem
Target family: TAO subfamily (type: enzyme)
Target: TAO kinase 3

Ligand: AMG28 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.349999904632568 pIC50
Reference (Journal): Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of &#x3b2;-Coronaviruses.
Published in: J Med Chem

Ligand: compound 89S [PMID: 19115845] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pIC50
Reference (Journal): First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Published in: J Med Chem

Ligand: compound 1 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R20</i>

Ligand: methoxsalen (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1954)
Primary target: no
Median affinity: 4.920000076293945 pEC50
Reference (Journal): Phytochemicals from Ruta graveolens Activate TAS2R Bitter Taste Receptors and TRP Channels Involved in Gustation and Nociception.
Published in: Molecules
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R10</i>

Ligand: cucurbitacin B (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pEC50
Reference (Journal): The human bitter taste receptor TAS2R10 is tailored to accommodate numerous diverse ligands.
Published in: J Neurosci

Ligand: denatonium (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.130000114440918 pEC50
Reference (Journal): The human bitter taste receptor TAS2R10 is tailored to accommodate numerous diverse ligands.
Published in: J Neurosci

Ligand: haloperidol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1967)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: strychnine (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.480000019073486 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R9</i>

Ligand: procainamide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity: 2.549999952316284 pEC50
Reference (Journal): Bitter taste receptors influence glucose homeostasis.
Published in: PLoS One

Ligand: pirenzepine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 2.740000009536743 pEC50
Reference (Journal): Bitter taste receptors influence glucose homeostasis.
Published in: PLoS One

Ligand: ofloxacin (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1990), UK (1992)
Primary target: no
Median affinity: 3.700000047683716 pEC50
Reference (Journal): Bitter taste receptors influence glucose homeostasis.
Published in: PLoS One
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R8</i>

Ligand: S7958 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.
Published in: J Med Chem

Ligand: S6821 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.
Published in: J Med Chem

Ligand: parthenolide (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: oleuropein (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.239999771118164 pEC50
Reference (Journal): Activation of specific bitter taste receptors by olive oil phenolics and secoiridoids.
Published in: Sci Rep

Ligand: chloramphenicol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1959)
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: andrographolide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.9600000381469727 pEC50
Reference (Journal): Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.
Published in: J Med Chem
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R7</i>

Ligand: malvidin-3-glucoside (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.900000095367432 pEC50
Reference (Journal): Different phenolic compounds activate distinct human bitter taste receptors.
Published in: J Agric Food Chem

Ligand: grandinin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.610000133514404 pEC50
Reference (Journal): Human Bitter Taste Receptors Are Activated by Different Classes of Polyphenols.
Published in: J Agric Food Chem

Ligand: cromoglicic acid (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: no
Median affinity: 2.3499999046325684 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R5</i>

Ligand: Procyanidin C2 (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.449999809265137 pEC50
Reference (Journal): Different phenolic compounds activate distinct human bitter taste receptors.
Published in: J Agric Food Chem

Ligand: epigallocatechin-3-gallate (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.909999847412109 pEC50
Reference (Journal): Human Bitter Taste Receptors Are Activated by Different Classes of Polyphenols.
Published in: J Agric Food Chem

Ligand: 1,10-Phenanthroline (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R50</i>

Ligand: andrographolide (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.639999866485596 pEC50
Reference (Journal): The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentin.
Published in: J Agric Food Chem

Ligand: amarogentin (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentin.
Published in: J Agric Food Chem
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R4</i>

Ligand: stevioside (Natural product)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 3.4700000286102295 pEC50
Reference (Journal): Human psychometric and taste receptor responses to steviol glycosides.
Published in: J Agric Food Chem

Ligand: L-Trp-Trp-Trp (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.519999980926514 pEC50
Reference (Journal): Amino acids and peptides activate at least five members of the human bitter taste receptor family.
Published in: J Agric Food Chem

Ligand: colchicine (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2009)
Primary target: no
Median affinity: 2.990000009536743 pEC50
Reference (Journal): The molecular receptive ranges of human TAS2R bitter taste receptors.
Published in: Chem Senses

Ligand: azithromycin (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA & UK (1991)
Primary target: no
Median affinity: 4.130000114440918 pEC50
Reference (Journal): Chemosensory bitter taste receptors (T2Rs) are activated by multiple antibiotics.
Published in: FASEB J

Ligand: abscisic acid (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.460000038146973 pIC50
Reference (Journal): Abscisic Acid Acts as a Blocker of the Bitter Taste G Protein-Coupled Receptor T2R4.
Published in: Biochemistry
Target family: Taste 2 receptors (type: gpcr)
Target: <i>TAS2R41</i>

Ligand: chloramphenicol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1959)
Primary target: no
Median affinity:  -
Reference (Journal): Major haplotypes of the human bitter taste receptor TAS2R41 encode functional receptors for chloramphenicol.
Published in: Biochem Biophys Res Commun